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PreviewsFurther studies will determine whether
these disparate processes involve similar
mechanisms. Of clinical importance, the
dependence of Notch1-induced T-ALL
on persistent Hes1 signals provides the
impetus to further test Hes1 pathway
inhibitors, which may also be relevant to
tumors where Hes1 is activated indepen-
dently of Notch.
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The mechanisms that direct cell-type-specific peroxisome proliferator-activated receptor (PPAR) gene
programs are poorly understood. In this issue of Immunity, Szanto et al. (2010) identify signal transducer
and activator of transcription 6 as a transcriptional switch that licenses PPARg-dependent gene expression
in macrophages and dendritic cells.Macrophages are central components of
the innate immune system that are critical
for host defense. Found in almost all
tissues, they exhibit wide heterogeneity
and acquire a variety of functional pheno-
types depending on the external milieu.
For example, dendritic cells and macro-
phages present foreign antigens and
coordinate inflammatory responses trig-
gered by microbial pathogens through
the production of proinflammatory
factors. In other contexts, they clear
apoptotic cells and facilitate tissue re-
modeling and resolution of inflammation
through production of anti-inflammatory
mediators. Classical activation of macro-
phages (M1 phenotype) is induced by T
helper 1 (Th1) cell inflammatory cytokines
such as tumor necrosis factor a (TNFa)
and interferon-g (IFNg) and by pathogen
activation of Toll-like receptors (TLRs).
M1 activation leads to a coordinated
inflammatory response that primes cells
to deal with pathogens. Alternative activa-
tion of macrophages (M2 phenotype) canbe triggered by Th2 cell-activated T cells,
mast cells, basophils, eosinophils, or
macrophages through release of the cyto-
kines interleukin (IL)-4 or IL-13. Alternative
activation has been implicated in parasitic
infections, allergy, tissue repair, and in-
flammation. Although it is useful to lump
macrophages into the M1 and M2 cate-
gories for the purposes of broad discus-
sion, it is likely that a continuum of pheno-
types between these rigid categories is
adopted by endogenous macrophages,
depending on the cellular context.
In this issue of Immunity, Szanto et al.
(2010) elucidate a mechanism whereby
alternative macrophage activation leads
to enhanced peroxisome proliferator-acti-
vated receptor g (PPARg)-dependent
gene expression. PPARg is a ligand-acti-
vated transcription factor that was origi-
nally characterized as a master regulator
of adipogenesis. PPARs form obligate
heterodimers with retinoid X receptors
(RXRs) that bind to cis-regulatory
elements (PPREs) found in proximalpromoters, introns, or distal regions of
their target genes. In adipose cells,
PPARg regulates the expression of genes
involved in differentiation, lipid uptake,
and triglyceride storage. PPARg is also
the target of a popular class of antidia-
betic drugs, thiazolidinediones, that act
as direct ligands of the receptor.
In addition to adipose tissue, PPARg is
highly expressed in macrophages and is
induced during monocyte differentiation
and dendritic cell maturation. It has been
recognized for several years that the gene
expression programs induced by PPARg
ligands in adipocytes and macrophages
are only partially overlapping, raising the
question of how cell-type specificity is
accomplished. Lazar and colleagues
have recently reported that binding sites
for the transcription factor PU.1 are
present, together with PPREs, in many
macrophage-expressed PPARg target
genes (Lefterova et al., 2010). This charac-
teristic distinguishes them fromadipocyte-
selective target genes, which commonlyovember 24, 2010 ª2010 Elsevier Inc. 647
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Figure 1. IL-4 Facilitates PPARg-Dependent Gene Expression
through STAT6 Signaling
In macrophages, PPARg binds to the adipocyte PPAR response element (Adi-
poPPRE) as well as the macrophage PPAR response element (MacPPRE) in
the Fabp4 gene (encoding aP2). Maximal PPARg activity and expression of
aP2 is dependent on STAT6 binding to a STAT6 response element (S6RE)
adjacent to the MacPPRE.
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adjacent to the PPREs.
The molecular basis for
differential engagement of
PPARg responses between
different types of macro-
phages and dendritic cells
has also been an important
question in the field. Glass
and colleagues reported
a number of years ago that
the Th2 cell cytokine IL-4 was
a strong inducer of PPARg
expression in macrophages
(Huang et al., 1999). Subse-
quent studies reported that
an active PPARg pathway is
a prominent feature of alterna-
tively activated (M2) macro-
phages and that M2-type res-
ponses were compromised in
the absenceofPPARgexpres-
sion (Odegaard et al., 2007).
PPARg expression is impor-
tant for the full expression of
certain genes characteristic of
M2 macrophages, especially
the gene encoding arginase I,
a direct PPAR target (Ode-gaard et al., 2007; Gallardo-Soler et al.,
2008). However, the degree to which
PPARgactivity is required for theestablish-
ment of broader IL-4 responses and the
various biological functions of alternatively
activated macrophages has continued to
be an active area of investigation (Marathe
et al., 2009). In particular, the transcrip-
tional underpinnings of IL-4-PPARg cross-
talk in alternatively activatedmacrophages
have remained poorly understood.
Szanto et al. (2010) began by investi-
gating how the PPARg pathway was
altered in various types of macrophages
anddendritic cells. They found that activa-
tion of macrophages with IL-4 drove the
expression of PPARg itself and enhanced
target gene expression in response to
the PPARg ligand rosiglitazone. In
contrast, classical activation of the cells
with IFNg, TNFa, or lipopolysaccharide
(LPS) inhibited the response to
rosiglitazone, despite the fact that in-
creased PPARg expression was also
observed with LPS treatment. Crosstalk
between IL-4 and PPARg signaling was
further supported by global gene expres-
sion analysis. Remarkably, the authors
found that rosiglitzone induced 635 genes
in the presence of IL-4 but only 120 genes648 Immunity 33, November 24, 2010 ª2010in the absence of IL-4. Moreover, both the
magnitude of induction and the number of
genes regulated by PPARg were affected
by IL-4. Thus, robust activation of PPARg
signaling in macrophages and dendritic
cells was highly dependent on IL-4 stimu-
lation, and this could not simply be
explainedbydifferences inPPARgexpres-
sion. Importantly, the requirement for IL-4
in PPARg responses was also observed in
mouse and human macrophages as well
as in dendritic cells. These findings sug-
gested the existence of one or more tran-
scription factors that ‘‘gate’’ or ‘‘license’’
the PPARg response in myeloid cells.
The authors went on to address the
reciprocal question of the degree to which
PPARg was required for the gene expres-
sion response to IL-4. In contrast to the
strong requirement of PPARg target
genes for IL-4 costimulation, the IL-4 tran-
scriptome was modestly affected in the
absence of the gene encoding PPARg in
macrophages. For example, induction of
the alternative activation markers YM1 or
FIZZ1 by IL-4 proceed normally in wild-
type or PPARg-deficient peritoneal or
bone marrow-derived macrophages.
To determine how IL-4 signaling was
potentiating PPARg activity on a molec-Elsevier Inc.ular basis, Szanto et al.
(2010) employed pharmaco-
logical inhibitors to interro-
gate various signaling
pathways known to act down-
stream of the IL-4 receptor.
The finding that WHI-P131,
an inhibitor of the Janus
kinase (Jak) 3 pathway,
antagonized the induction of
the lipid-binding protein aP2
by rosiglitazone led the
authors to hone in on signal
transducer and activators of
transcription6 (STAT6), a tran-
scription factor known to
mediate IL-4 signaling in
macrophages. Using macro-
phages that were genetically
deficient in STAT6 expres-
sion, the authors were able
to show that PPARg signaling
in IL-4-treated macrophages
was highly dependent on
STAT6. For example, PPARg
target genes such as Fabp4
(encoding aP2) and Angptl4
(encoding PGAR) showed
a muted response torosiglitazone in Stat6/ compared to
wild-typemacrophages. Global transcrip-
tional profiling confirmed that a majority
of PPARg-responsive genes required
STAT6 for full activation in macrophages.
These findings led the authors to
hypothesize that STAT6 might be regu-
lating PPARg target genes by binding to
their regulatory sequences directly. This
idea was validated initially by coexpress-
ing STAT6 and PPARg in transient
transfection assays along with an Fabp4-
luciferase reporter. Promoter activity was
additively responsive to STAT6 and
PPARg, consistent with a direct effect on
the Fabp4promoter. The authors then
analyzed the Fabp4 gene to identify the
response elements involved. Previous
studies in adipocytes showed that PPARg
binds to a PPRE in the distal region of the
Fabp4 enhancer, approximately 5.4 kb
from the transcriptional start site (Tonto-
noz et al., 1994). Interestingly, Szanto
et al. (2010) identified an additional, previ-
ously unknown response element, which
they termed MacPPRE to distinguish it
from the adipocyte PPRE. Moreover, this
regulatory region contained a highly
conserved STAT6 binding site adjacent
to the MacPPRE (Figure 1). Mutation of
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nated the ability of IL-4 to facilitate activa-
tion of the Fabp4 promoter.
An important remaining question was
whether PPARg or STAT6 could be local-
ized to the region of the MacPPRE in the
endogenous Fabp4 gene in macro-
phages. To address this possibility, the
authors employed chromatin immunopre-
cipitation (ChiP) assays using antibodies
for STAT6 and PPARg. Indeed, PPARg
was shown to occupy both the adipocyte
PPRE and the identified MacPPRE in
macrophages. Unexpectedly, however,
STAT6 was enriched in the region of the
adipocyte PPRE as well as the region of
the MacPPRE (which contains the
STAT6 element). Although this finding
may simply reflect the limited resolution
of the ChiP assay, a more provocative
interpretation is that STAT6 may interact
with PPARg without having to bind to
DNA, perhaps serving as a coactivator in
macrophages. In support of this idea,
the authors showed that STAT6 could be
pulled down with purified PPARg protein
in biochemical interaction assays. Finally,
consistent with the common requirement
of many macrophage PPARg target
genes for IL-4 signaling, ChIP assays
revealed diminished PPARg occupancy
on the Angptl4, Cd36, Fabp4, and
Scd1 promoters in STAT6-deficient
macrophages.
In summary, Szanto et al. (2010) have
outlined a role for the IL-4-dependent
transcription factor STAT6 as a licensingfactor for PPARg activity in macrophages
and dendritic cells. These studies provide
additional mechanistic support for the
emerging concept that cell-type-specific
gene regulation is dependent on a combi-
natorial code of transcriptional regulators.
In addition, the work brings insight into
how this code is implemented on specific
gene promoters. These findings also
extend and clarify prior work by posi-
tioning PPARg downstream rather than
upstream of IL-4 in the alternative macro-
phage activation cascade (Odegaard
et al., 2007). Furthermore, the identities
of the genes coregulated by IL-4 and
PPARg are suggestive of a discrete role
for PPARg signaling in a transcriptional
program for handling lipids after phagocy-
tosis of apoptotic cells or parasites. In
agreement with this possibility, recent
studies have reported a role for the related
nuclear receptor PPARd in phagocytic
responses (Mukundan et al., 2009).
Several questions are raised by the
findings of Szanto et al. (2010) that will
undoubtedly be the focus of additional
research in the coming years. For
example, what is the role of PPAR-depen-
dent gene expression in the different
functions of alternatively activatedmacro-
phages and dendritic cells in various
biological contexts? What is the relative
importance of lipid metabolic and inflam-
matory gene expression in these
settings? What is the natural ligand for
PPARg in macrophages and how does
this fit with the biology of IL-4? Lastly,Immunity 33, Ngiven the centrality of metabolism and
inflammation in human disorders such as
atherosclerosis and diabetes, it will be
important to determine the relevance of
PPARg-STAT6 interaction for disease
pathogenesis, immunological responses,
and therapeutic intervention.REFERENCES
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